These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 23062565)

  • 1. Cardiovascular effects of noninsulin, glucose-lowering agents: need for more outcomes data.
    Joshi PH; Kalyani RR; Blumenthal RS; Donner TW
    Am J Cardiol; 2012 Nov; 110(9 Suppl):32B-42B. PubMed ID: 23062565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
    Sharma A; Pagidipati NJ; Califf RM; McGuire DK; Green JB; Demets D; George JT; Gerstein HC; Hobbs T; Holman RR; Lawson FC; Leiter LA; Pfeffer MA; Reusch J; Riesmeyer JS; Roe MT; Rosenberg Y; Temple R; Wiviott S; McMurray J; Granger C
    Circulation; 2020 Mar; 141(10):843-862. PubMed ID: 31992065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety.
    Fitchett D; Cheng A; Connelly K; Goldenberg R; Goodman SG; Leiter LA; Lonn E; Paty B; Poirier P; Stone J; Thompson D; Yale JF; Mancini GBJ
    Can J Cardiol; 2017 Jul; 33(7):940-942. PubMed ID: 28668144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ
    Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New developments in type 2 diabetes mellitus: combination therapy with a thiazolidinedione.
    Braunstein S
    Clin Ther; 2003 Jul; 25(7):1895-917. PubMed ID: 12946541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones.
    Florkowski CM
    Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies.
    Brown NJ
    J Am Soc Hypertens; 2012; 6(3):163-8. PubMed ID: 22433315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cardiovascular effects and safety of glucose-lowering drugs: current situation].
    Masmiquel L
    Semergen; 2014 Mar; 40(2):80-8. PubMed ID: 24655910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.
    Boussageon R; Bejan-Angoulvant T; Saadatian-Elahi M; Lafont S; Bergeonneau C; Kassaï B; Erpeldinger S; Wright JM; Gueyffier F; Cornu C
    BMJ; 2011 Jul; 343():d4169. PubMed ID: 21791495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus.
    Huang ES; Meigs JB; Singer DE
    Am J Med; 2001 Dec; 111(8):633-42. PubMed ID: 11755507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of diabetes in metabolic syndrome].
    Pelikánova T
    Vnitr Lek; 2009; 55(7-8):637-45. PubMed ID: 19731868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of incretin-based therapies in the management of type 2 diabetes.
    Bandyopadhyay P
    Drug News Perspect; 2009 Nov; 22(9):559-67. PubMed ID: 20072733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of glucose-lowering therapy on cardiovascular outcomes.
    Standl E; Müller M; Schnell O
    Best Pract Res Clin Endocrinol Metab; 2009 Jun; 23(3):401-11. PubMed ID: 19520312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihyperglycemic drugs and cardiovascular outcomes in type 2 diabetes.
    Ganda OP
    Cleve Clin J Med; 2016 May; 83(5 Suppl 1):S11-7. PubMed ID: 27176677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
    Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
    Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.